The cancer vaccines market was valued at USD 11.3 billion in 2025 and is projected to reach USD 12.6 billion by 2026-end, expanding at a 12.0% CAGR from 2026 to 2036 to reach USD 39.3 billion by 2036. Growth is being supported by advances in mRNA vaccine platforms, personalized neoantigen approaches, recombinant technologies, and combination therapies...